Inovio Pharmaceuticals Inc (INO)
10.16
+0.39
(+3.99%)
USD |
NASDAQ |
May 31, 16:00
10.31
+0.15
(+1.48%)
Pre-Market: 08:45
Inovio Pharmaceuticals Accounts Payable (Quarterly): 8.297M for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.297M |
December 31, 2023 | 4.648M |
September 30, 2023 | 3.904M |
June 30, 2023 | 10.36M |
March 31, 2023 | 12.61M |
December 31, 2022 | 21.08M |
September 30, 2022 | 14.27M |
June 30, 2022 | 39.57M |
March 31, 2022 | 39.52M |
December 31, 2021 | 27.97M |
September 30, 2021 | 29.15M |
June 30, 2021 | 31.87M |
March 31, 2021 | 26.74M |
December 31, 2020 | 1.468M |
September 30, 2020 | 24.33M |
June 30, 2020 | 17.73M |
March 31, 2020 | 11.28M |
December 31, 2019 | 7.649M |
September 30, 2019 | 10.25M |
June 30, 2019 | 14.04M |
March 31, 2019 | 16.96M |
December 31, 2018 | 11.02M |
September 30, 2018 | 18.02M |
June 30, 2018 | 13.21M |
March 31, 2018 | 17.12M |
Date | Value |
---|---|
December 31, 2017 | 8.492M |
September 30, 2017 | 23.31M |
June 30, 2017 | 17.33M |
March 31, 2017 | 15.00M |
December 31, 2016 | 6.993M |
September 30, 2016 | 16.68M |
June 30, 2016 | 13.31M |
March 31, 2016 | 12.31M |
December 31, 2015 | 4.457M |
September 30, 2015 | 13.33M |
June 30, 2015 | 9.485M |
March 31, 2015 | 4.450M |
December 31, 2014 | 2.032M |
September 30, 2014 | 4.792M |
June 30, 2014 | 5.990M |
March 31, 2014 | 6.030M |
December 31, 2013 | 2.388M |
September 30, 2013 | 4.515M |
June 30, 2013 | 3.382M |
March 31, 2013 | 2.945M |
December 31, 2012 | 1.040M |
September 30, 2012 | 3.134M |
June 30, 2012 | 3.523M |
March 31, 2012 | 3.317M |
December 31, 2011 | 1.161M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
1.468M
Minimum
Dec 2020
39.57M
Maximum
Jun 2022
17.84M
Average
14.15M
Median
Accounts Payable (Quarterly) Benchmarks
Stereotaxis Inc | 3.307M |
Novavax Inc | 57.72M |
Sangamo Therapeutics Inc | 15.47M |
Vaxart Inc | 3.978M |
Capricor Therapeutics Inc | -- |